Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure ... causes considerable weight loss, research is lacking ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce ... and achieved 15.7% weight loss compared to a 2.2% loss in the control group. A key difference between SUMMIT and Novo ...

“We believe the data from this study will demonstrate that the combination of MC4R + GLP-1/GIP agonists may result in additive and synergistic effects on patient weight loss, and importantly ... of ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide ...

Weight-loss drugs are now classed as "high risk" medicines, requiring extra safeguards, and are offered on the NHS with very strict criteria. Semaglutide and tirzepatide were first used to help ...

Global Healthy Living Foundation Says Hims & Hers Health Super Bowl ad omits safety risks and side effects of its weight loss drug.

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

MORGANTOWN – WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

At least nine patients using the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and tirzepatide developed ... and progressive loss of vision. The single patient who developed ...